Airexar Spiromax Europese Unie - Estlands - EMA (European Medicines Agency)

airexar spiromax

teva b.v. - salmeterol, fluticasone propionaat - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - airexar spiromax on näidustatud kasutamiseks täiskasvanutel vanuses 18 aastat ja vanemad ainult. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. krooniline obstruktiivne kopsuhaigus (copd)airexar spiromax on näidustatud sümptomaatiline ravi patsientidel, kellel copd), koos fev1.

ANAPEN süstelahus süstlis Estland - Estlands - Ravimiamet

anapen süstelahus süstlis

bioprojet pharma - epinefriin (adrenaliin) - süstelahus süstlis - 300mcg 0.3ml 0.3ml 1tk

ANAPEN süstelahus süstlis Estland - Estlands - Ravimiamet

anapen süstelahus süstlis

bioprojet pharma - epinefriin (adrenaliin) - süstelahus süstlis - 150mcg 0.3ml 0.3ml 1tk

BroPair Spiromax Europese Unie - Estlands - EMA (European Medicines Agency)

bropair spiromax

teva b.v. - salmeterol xinafoate, fluticasone propionaat - astma - ravimid hingamisteede obstruktiivsete haiguste, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Seffalair Spiromax Europese Unie - Estlands - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Wilzin Europese Unie - Estlands - EMA (European Medicines Agency)

wilzin

recordati rare diseases - tsink - hepatolentikulaarne degeneratsioon - muud alimentary seedetrakti ja ainevahetust tooted, - wilsoni tõve ravi.

DOXORUBICIN ACTAVIS infusioonilahuse kontsentraat Estland - Estlands - Ravimiamet

doxorubicin actavis infusioonilahuse kontsentraat

actavis group ptc ehf. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 75ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 10ml 10tk; 2mg 1ml 5ml 10tk

DOXORUBICIN ACTAVIS süstelahuse pulber Estland - Estlands - Ravimiamet

doxorubicin actavis süstelahuse pulber

actavis group ptc ehf. - doksorubitsiin - süstelahuse pulber - 10mg 1tk

DOXORUBICIN ACCORD 2 MG/ML infusioonilahuse kontsentraat Estland - Estlands - Ravimiamet

doxorubicin accord 2 mg/ml infusioonilahuse kontsentraat

accord healthcare b.v. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 10ml 1tk; 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 5ml 1tk

DOKSORUBITSIIN MYLAN infusioonilahuse kontsentraat Estland - Estlands - Ravimiamet

doksorubitsiin mylan infusioonilahuse kontsentraat

mylan s.a.s. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 5ml 1viaal; 2mg 1ml 100ml 1viaal; 2mg 1ml 10ml 1viaal; 2mg 1ml 25ml 1viaal